As part of its public health strategy, Alberta offered SARS-CoV-2 molecular testing beginning in January 2020 for travel-related requests using a gel-based reverse transcriptase PCR (RT-PCR) assay (COVID-19-specific and pan-coronavirus) (4 (link)). From February 2020 onward, laboratory-developed real-time RT-PCR assays targeting the SARS-CoV-2 envelope (E) and/or RNA-dependent-RNA-polymerase (RdRp) were implemented, followed by a laboratory-developed E/RdRp/MS2 multiplex assay or Seegene (2019-nCoV assay, Seegene), Xpert (Xpress SARS-CoV-2, Cepheid), Aptima (SARS-CoV-2 assay, Hologic), BD Max (BioGX SARS-CoV-2, BD Molecular Diagnostics), Simplexa (COVID-19 direct test, DiaSorin), or cobas 6800 (SARS-CoV-2 test, Roche) testing (depending on laboratory testing location) for all symptomatic patients (27 (link), 28 (link)). Between 29 May 2020 and 4 November 2020, broad asymptomatic testing was made available to all Albertans.
2019 ncov assay
Manufactured by Seegene
The 2019-nCoV assay is a real-time RT-PCR (reverse transcription-polymerase chain reaction) test developed by Seegene. It is designed to detect the presence of the 2019 novel coronavirus (SARS-CoV-2), the virus that causes COVID-19. The assay targets specific genetic sequences of the virus to determine if a sample is positive for the virus.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using 2019 ncov assay
1
SARS-CoV-2 Testing Strategies in Alberta
2
SARS-CoV-2 Testing Strategies in Alberta
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
As part of its public health strategy, Alberta offered SARS-CoV-2 molecular testing beginning in January 2020 for travel-related requests using a gel-based reverse transcriptase PCR (RT-PCR) assay (COVID-19-specific and pan-coronavirus) (4 (link)). From February 2020 onward, laboratory-developed real-time RT-PCR assays targeting the SARS-CoV-2 envelope (E) and/or RNA-dependent-RNA-polymerase (RdRp) were implemented, followed by a laboratory-developed E/RdRp/MS2 multiplex assay or Seegene (2019-nCoV assay, Seegene), Xpert (Xpress SARS-CoV-2, Cepheid), Aptima (SARS-CoV-2 assay, Hologic), BD Max (BioGX SARS-CoV-2, BD Molecular Diagnostics), Simplexa (COVID-19 direct test, DiaSorin), or cobas 6800 (SARS-CoV-2 test, Roche) testing (depending on laboratory testing location) for all symptomatic patients (27 (link), 28 (link)). Between 29 May 2020 and 4 November 2020, broad asymptomatic testing was made available to all Albertans.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!